FDA Required to Provide Detailed Q1/Q2 Sameness Feedback Under New Federal Law
核心洞察
A new federal law signed on February 3, 2026, requires the FDA to provide specific feedback on why generic drug (搜索) formulations fail Q1/Q2 sameness requirements, ending years of binary yes/no responses.
The legislation mandates FDA disclosure of specific inactive ingredients causing differences and quantitative deviation amounts, addressing long-standing development uncertainty for ANDA (搜索) applicants.
The change particularly benefits developers of complex generic products including parenteral, ophthalmic, and otic drugs (搜索), which must demonstrate Q1/Q2 sameness with reference listed drugs.
The Food and Drug Administration must now provide detailed explanations when generic drug (搜索) formulations fail to meet qualitative and quantitative (Q1/Q2) sameness requirements, following the enactment of new federal legislation that promises to transform the abbreviated new drug application (ANDA (搜索)) development process.
President Trump signed H.R.7148, the Consolidated Appropriations Act, 2026, into law on February 3, 2026. Section 6703 of the Act, titled "Increasing Transparency in Generic Drug (搜索) Applications," amends the Federal Food, Drug, and Cosmetic Act to require the FDA to provide specific feedback on Q1/Q2 sameness determinations.
Enhanced Disclosure Requirements
Under the new law, when ANDA (搜索) applicants submit controlled correspondence requesting Q1/Q2 sameness assessments, the FDA must inform applicants whether their proposed generic drug (搜索) is Q1/Q2 the same as the listed drug. Crucially, if the FDA determines the proposed generic is not Q1/Q2 the same, the agency must identify the specific inactive ingredients that create the difference and, for any ingredient with a quantitative deviation, disclose the amount of the deviation.
This represents a significant departure from the FDA's historical approach, which was constrained by statutory and regulatory protections for trade secrets and confidential commercial information. Previously, feedback was typically limited to a binary determination of whether a proposed formulation was or was not Q1/Q2 the same as the listed drug, leaving sponsors to infer the underlying reasons through reverse engineering and iterative exchanges with the FDA.
Impact on Complex Generic Development
The change particularly addresses development uncertainty for ANDA (搜索) applicants developing complex generic products. Q1/Q2 sameness is often the first and most consequential question in formulation development for parenteral, ophthalmic, and otic products, where regulatory requirements mandate Q1/Q2 sameness. The FDA's feedback at this stage can determine whether a development program proceeds or stalls.
Prior to the Act, ANDA (搜索) filers were left speculating about which inactive ingredient was dissimilar and attempting to develop their own "precedent" from prior ANDAs. This old system often led to a back-and-forth process where ANDA filers attempted numerous alternatives and awaited FDA's final determination, or gave up their pursuit entirely.
Regulatory Safeguards and Limitations
The new law expressly limits the FDA's disclosure authority to identifying the ingredient causing Q1/Q2 differences and the amount of any quantitative deviation. It makes clear that it does not otherwise permit disclosure of nonpublic formulation information for listed drugs or alter the treatment of that information as trade secrets or confidential commercial information.
Additionally, the FDA cannot rescind a determination that a generic is Q1/Q2 the same as the reference listed drug unless there has been a change to the reference drug's formulation and the prior formulation was deemed withdrawn for reasons of safety or effectiveness. However, if the FDA determines that an error was made, the agency can rescind such a determination once it provides notice and a copy of the written determination to the ANDA (搜索) filer.
Implementation Timeline
Congress directed the FDA to issue draft guidance within one year describing how the agency will determine Q1/Q2 sameness under the new statutory provision. The guidance is expected to address pH adjusters, which were expressly mentioned in Section 6703, following the release of final guidance on waiver requests in November.
Notably, the statute is effective immediately regardless of the timing of the guidance. ANDA (搜索) applicants may immediately begin requesting Q1/Q2 assessments through controlled correspondence and expect the FDA to provide more detailed feedback.
The increased transparency is expected to facilitate a smoother and less costly ANDA (搜索) process, support informed formulation decisions, enable targeted regulatory engagement, and promote efficient allocation of development resources, potentially accelerating generic drug (搜索) market entry.